NCT01652560Unknown不适用
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
LiNanlin,Ph.D, Chief Physician,Clinical Professor1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HER2-negative breast cancer patients
- •Without surgery
- •Plans to neoadjuvant chemotherapy
排除标准
- •HER2-positive breast cancer patients
- •Post-operative patients
研究组 & 干预措施
bevacizumab combined neoadjuvant chemotherapy
干预措施: bevacizumab (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: From enrollment to disease progression
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
次要结局
- overall response(From enrollment to disease progression)
研究者
LiNanlin,Ph.D, Chief Physician,Clinical Professor
The department of Vascular endocrine surgery
Xijing Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity LymphedemaLymphedemaNCT00318513Premiere Oncology of Arizona35
已完成
1 期
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid TumorsSolid TumorNCT00786669Children's Hospital Medical Center, Cincinnati13
已完成
不适用
Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian CancerOvarian CancerNCT03367182Yonsei University50
已完成
1 期
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)Degenerative MyopiaChoroidal NeovascularizationPathological MyopiaNCT00407719Johns Hopkins University10
撤回
2 期
A Study of Bevacizumab to Prevent Malignant AscitesMalignant AscitesNCT00908219Baylor College of Medicine